Phaseline

Targets › GAG

GAG: drug programs, companies and trials

2 programs from 1 company in 28 trials: 18 Phase 2, 7 Phase 3, 2 Phase 4, 1 Phase 1; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on GAG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gilead SciencesLenacapavir
Structural capsid protein inhibitor
CA, CPSF6, GAG, PROT, UNKNOWN, CAPSIDPhase 3Pre-Exposure Prophylaxis of HIV Infection; HIV Pre-exposure Prophylaxis; HIV Infections; HIV-1-infection …Mar 2027
Gilead SciencesISL/LEN FDC
Fixed-dose combination of nucleotide reverse transcriptase translocation inhibitor and HIV
POLB, GAGPhase 2HIV-1 InfectionMar 2028

Conditions

HIV-1-infection (10) Pre-Exposure Prophylaxis of HIV Infection (7) HIV-1 Infection (4) HIV Pre-exposure Prophylaxis (2) HIV Infections (1) HIV-1-Infection (1) HIV (1) HIV Prevention (1) Human Immunodeficiency Virus (1)

Modalities

mixed (1), small molecule (1)

Companies

Gilead Sciences (2)

Related targets

CA (1) CPSF6 (1) PROT (1) UNKNOWN (1) CAPSID (1) POLB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.